Related Experiment Video
Updated: Jul 16, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
CircMAP3K5 promotes cardiomyocyte apoptosis in diabetic cardiomyopathy by regulating miR-22-3p/DAPK2 Axis
Ming Shen1,2, Yuanbin Wu3, Libing Li1
1Department of Cardiovascular Surgery, The First Medical Center of PLA General Hospital, Beijing, China.
Insights
Circular RNA MAP3K5 (circMAP3K5) promotes diabetic cardiomyopathy by increasing cardiomyocyte apoptosis via the miR-22-3p/DAPK2 pathway. Targeting circMAP3K5 offers a potential therapeutic strategy for diabetic heart disease.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Genetics
Background:
- Diabetic cardiomyopathy (DCM) is a severe complication of diabetes with no effective treatments.
- Circular RNAs (circRNAs) are implicated in cardiac diseases, but the role of circRNA MAP3K5 (circMAP3K5) in DCM is unknown.
Purpose of the Study:
- To investigate the role and mechanism of circMAP3K5 in diabetic cardiomyopathy.
- To explore circMAP3K5 as a potential therapeutic target for DCM.
Main Methods:
- Microarray analysis identified circMAP3K5 in DCM rat hearts.
- In vitro studies used high glucose-induced H9c2 cardiomyocytes to assess circMAP3K5 function.
- Mechanistic studies involved assessing circMAP3K5's interaction with miR-22-3p and DAPK2.
Main Results:
- CircMAP3K5 expression is upregulated in DCM and by high glucose, promoting cardiomyocyte apoptosis.
- Depletion of circMAP3K5 reduced high glucose-induced apoptosis.
- CircMAP3K5 acts as a sponge for miR-22-3p, upregulating DAPK2 expression.
Conclusions:
- CircMAP3K5 promotes high glucose-induced cardiomyocyte apoptosis by regulating the miR-22-3p/DAPK2 axis.
- CircMAP3K5 is a conserved noncoding RNA and a potential therapeutic target for DCM.
Background:
Diabetic cardiomyopathy (DCM) is one of the serious complications of the accumulated cardiovascular system in the long course of diabetes. To date, there is no effective treatment available for DCM. Circular RNA (circRNA) is a novel r2egulatory RNA that participates in a variety of cardiac pathological processes. However, the regulatory role of circular RNA MAP3K5 (circMAP3K5) in DCM is largely unclear.
Methods And Results:
Microarray analysis of DCM rats' heart circular RNAs was performed and the highly species-conserved circRNA mitogen-activated protein kinase kinase kinase 5 (circMAP3K5) was identified, which participates in DCM processes. High glucose-provoked cardiotoxicity leads to the up-regulation of circMAP3K5, which mechanistically contributes to cardiomyocyte cell death. Also, in high glucose-induced H9c2 cardiomyocytes, the level of apoptosis was significantly increased, as well as the expression of circMAP3K5. In contrast, the depletion of circMAP3K5 could reduce high glucose-induced apoptosis in cardiomyocytes. In terms of mechanism, circMAP3K5 acts as a miR-22-3p sponge and miR-22-3p directly target death-associated protein kinase 2 (DAPK2) in H9c2 cardiomyocytes, where in circMAP3K5 upregulates DAPK2 expression by targeting miR-22-3p. Moreover, we also found that miR-22-3p inhibitor and pcDNA DAPK2 could antagonize the protective effects brought by the depletion of circMAP3K5.
Conclusion:
CircMAP3K5 is a highly conserved noncoding RNA that is upregulated during DCM process. We concluded that circMAP3K5 promotes high glucose-induced cardiomyocyte apoptosis by regulating the miR-22-3p/DAPK2 axis. The results of this study highlight a novel and translationally important circMAP3K5-based therapeutic approach for DCM.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy

